MedTrace Logo

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

NCT05137847 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 118

Last updated 2023-12-12

No results posted yet for this study

Summary

The primary purpose of the study is to investigate the incidence of adverse drug reactions (ADRs) (ADR of special interest: capillary leak syndrome, infusion reaction, rhabdomyolysis, myelosuppression, infection, hepatic dysfunction, visual impairment/color blindness, ischemic heart disease/arrhythmia/cardiac failure, and severe skin disorders).

Conditions

  • Lymphoma, T-cell, Peripheral
  • Lymphoma, T-cell, Cutaneous

Interventions

DRUG

Remitoro

Intravenous infusion.

Sponsors & Collaborators

  • Eisai Inc.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-24
Primary Completion
2023-03-17
Completion
2023-03-17

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05137847 on ClinicalTrials.gov